Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough prostate cancer: first human trial of VIR-5500 begins

NCT ID NCT05997615

Recruiting now Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. About 437 participants will receive VIR-5500 alone or with another therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE REFRACTORY PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE REFRACTORY PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number: 100

    RECRUITING

    Melbourne, 3000, Australia

  • Investigational Site Number: 101

    RECRUITING

    Sydney, 2010, Australia

  • Investigational Site Number: 250

    RECRUITING

    Barcelona, 08035, Spain

  • Investigational Site Number: 251

    WITHDRAWN

    Barcelona, 08023, Spain

  • Investigational Site Number: 252

    RECRUITING

    Madrid, 28223, Spain

  • Investigational Site Number: 253

    RECRUITING

    Pamplona, 31008, Spain

  • Investigational Site Number: 254

    RECRUITING

    Madrid, 28027, Spain

  • Investigational Site Number: 300

    RECRUITING

    London, SM2 5PT, United Kingdom

  • Investigational Site Number: 400

    RECRUITING

    Seattle, Washington, 98109, United States

  • Investigational Site Number: 401

    RECRUITING

    Houston, Texas, 77030, United States

  • Investigational Site Number: 403

    RECRUITING

    Palo Alto, California, 94304, United States

  • Investigational Site number: 404

    RECRUITING

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.